Nucleic Acid Therapeutics

Can Toxicity of a DNA Drug Be Predicted and Minimized?

View email in a browser
Mary Ann Liebert, Inc., publishers ShareThis
background image
 

FOR IMMEDIATE RELEASE

PRESS RELEASE FROM MARY ANN LIEBERT, INC., PUBLISHERS

Contact: Vicki Cohn
Mary Ann Liebert, Inc., publishers (914) 740-2100
vcohn@liebertpub.com

Can Toxicity of a DNA Drug Be Predicted and Minimized?

New Rochelle, NY, August 26, 2013—New classes of therapeutic antisense oligonucleotides can have toxic effects on the liver. A novel machine learning-based approach used to predict the hepatotoxic potential of an antisense drug based on its chemical sequence is presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available free on the Nucleic Acid Therapeutics website.

Peter Hagedorn and coauthors from Santaris Pharma, Hørsholm, Denmark, and University of Copenhagen, Denmark, describe the use of machine learning techniques to develop a method of classifying therapeutic oligonucleotides based on their DNA sequence and modification patterns. Computers create a classification scheme linking this variation to a compound's potential to cause liver toxicity.

In the article “Hepatotoxic Potential of Therapeutic Oligonucleotides Can Be Predicted from Their Sequence and Modification Pattern,” the authors demonstrate the use of this approach to predict the hepatotoxicity of a validation set of oligonucleotides with 74% accuracy. They also use the classifier scheme to identify a therapeutic oligonucleotide with high potential liver toxicity and show how the drug could be redesigned to reduce its potential toxicity.

“As is true of all potential therapeutic entities, whether small molecules or nucleic acid-based drugs, it is critical to understand as much as possible about possible toxic effects before proceeding to clinical trials,” says Executive Editor Fintan Steele, PhD, SomaLogic, Inc., Boulder, CO. “The approach described by these authors holds great promise for maximizing the safety of in vivo testing and, we hope, the eventual clinical use of these new antisense-based compounds.”

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Fintan Steele, PhD (SomaLogic, Boulder, CO).

 
background image
   
Become a part of our World! Mary Ann Liebert, Inc., publishers

© 2013 Mary Ann Liebert, Inc., publishers. All Rights Reserved
IMPORTANT! You have received this email at . Make sure you receive your chosen Mary Ann Liebert e-Newsletters, alerts and news updates. Please add updates@liebertpubmail.com to your Address Book or Safe Senders List.

Refine your email preferences at Liebert Connect.
Privacy Policy | Unsubscribe

Mary Ann Liebert, Inc., 140 Huguenot Street, 3rd Floor, New Rochelle, NY, 10801-5215, USA



We respect your right to privacy - click here to view our policy.